Alamar Biosciences, Inc.(ALMR)

Biotechnology · Fremont, CA

$34.77-3.36 (-8.81%)

Delayed quote: Oct 6, 2026, 12:10 PM EDT

Alamar Biosciences (ALMR) EV/EBITDA: History & Chart | TGMCharts

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T16:15:35.102Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:15:35.102Z.

Quote observation: 2026-10-06T16:15:06.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 2,386,383,962
Total debt · period ending 2026-06-30: 51,406,000
Cash · period ending 2026-06-30: 132,969,000
TTM operating EBITDA · period ending 2026-06-30: N/A

FMP input reference: 026981202cadb8e73b6cbd63f18abfa8ffa74fea80ac6bbb32512047e0825b9f

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ALMR EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

ALMR Competitors' EV/EBITDA Ratio

ALMR

Alamar Biosciences, Inc.

Current

Market Cap

$2.39B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RXRX

Recursion Pharmaceuticals, Inc.

vs ALMR

Market Cap

$2.42B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CLOV

Clover Health Investments, Corp.

vs ALMR

Market Cap

$2.39B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ADMA

ADMA Biologics, Inc.

vs ALMR

Market Cap

$2.39B

EV/EBITDA Ratio

10.86x

TTM Avg

16.44x

3Y Avg

40.11x

5Y Avg

40.11x

NRIX

Nurix Therapeutics, Inc.

vs ALMR

Market Cap

$2.37B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LQDA

Liquidia Corporation

vs ALMR

Market Cap

$2.35B

EV/EBITDA Ratio

12.91x

TTM Avg

113.41x

3Y Avg

113.41x

5Y Avg

113.41x

IRON

Disc Medicine, Inc.

vs ALMR

Market Cap

$2.44B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HRMY

Harmony Biosciences Holdings, Inc.

vs ALMR

Market Cap

$2.30B

EV/EBITDA Ratio

7.44x

TTM Avg

6.56x

3Y Avg

7.54x

5Y Avg

13.22x

MRVI

Maravai LifeSciences Holdings, Inc.

vs ALMR

Market Cap

$2.27B

EV/EBITDA Ratio

15.70x

TTM Avg

9.40x

3Y Avg

61.74x

5Y Avg

31.90x

PRVA

Privia Health Group, Inc.

vs ALMR

Market Cap

$2.58B

EV/EBITDA Ratio

N/A

TTM Avg

70.45x

3Y Avg

91.30x

5Y Avg

141.66x

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Alamar Biosciences, Inc. (ALMR)	$2.39B	N/A	N/A	N/A	N/A
Recursion Pharmaceuticals, Inc. (RXRX)vs ›	$2.42B	N/A	N/A	N/A	N/A
Clover Health Investments, Corp. (CLOV)vs ›	$2.39B	N/A	N/A	N/A	N/A
ADMA Biologics, Inc. (ADMA)vs ›	$2.39B	10.86x	16.44x	40.11x	40.11x
Nurix Therapeutics, Inc. (NRIX)vs ›	$2.37B	N/A	N/A	N/A	N/A
Liquidia Corporation (LQDA)vs ›	$2.35B	12.91x	113.41x	113.41x	113.41x
Disc Medicine, Inc. (IRON)vs ›	$2.44B	N/A	N/A	N/A	N/A
Harmony Biosciences Holdings, Inc. (HRMY)vs ›	$2.30B	7.44x	6.56x	7.54x	13.22x
Maravai LifeSciences Holdings, Inc. (MRVI)vs ›	$2.27B	15.70x	9.40x	61.74x	31.90x
Privia Health Group, Inc. (PRVA)vs ›	$2.58B	N/A	70.45x	91.30x	141.66x

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics